Satellos Bioscience Inc (MSCLF)

$0.54 +0.01 (1.17%)
Market Cap 93.44M
Revenue (ttm) 0.00
Net Income (ttm) -20.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 21,400
Avg Vol 55,974
Day's Range N/A - N/A
Shares Out 176.31M
Stochastic %K 10%
Beta 1.06
Analysts Sell
Price Target $0.86

Company Profile

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an...

Industry: Biotechnology
Sector: Healthcare
Address:
Royal Bank Plaza, Suite 2800 South Tower 200 Bay Street, Toronto, Canada
Florestan
Florestan Oct. 21 at 3:22 PM
$MSCLF - First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled - 11-month open-label study will evaluate functional outcomes, safety, muscle composition by MRI, and serum biomarkers - Results following initial 3 months of treatment anticipated in early 2026, quarterly thereafter - Planning underway to broaden LT-001 study protocol to enroll new adult patients in Australia and open the study in the U.S., subject to regulatory and clinical site approvals https://ir.satellos.com/news/news-details/2025/Satellos-Announces-First-Adult-Patient-Dosed-in-LT-001-an-Open-Label-Long-Term-Follow-Up-Study-of-SAT-3247-in-Duchenne-Muscular-Dystrophy/default.aspx
0 · Reply
Florestan
Florestan Oct. 21 at 3:21 PM
$MSCLF - First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled - 11-month open-label study will evaluate functional outcomes, safety, muscle composition by MRI, and serum biomarkers - Results following initial 3 months of treatment anticipated in early 2026, quarterly thereafter - Planning underway to broaden LT-001 study protocol to enroll new adult patients in Australia and open the study in the U.S., subject to regulatory and clinical site approvals https://ir.satellos.com/news/news-details/2025/Satellos-Announces-First-Adult-Patient-Dosed-in-LT-001-an-Open-Label-Long-Term-Follow-Up-Study-of-SAT-3247-in-Duchenne-Muscular-Dystrophy/default.aspx
0 · Reply
Florestan
Florestan Oct. 13 at 5:07 PM
$MSCLF https://www.biospace.com/press-releases/satellos-announces-new-data-further-demonstrating-safety-tolerability-and-functional-impact-of-sat-3247-in-first-in-human-trial-of-adults-with-duchenne-muscular-dystrophy
0 · Reply
theoptionsplug
theoptionsplug Oct. 10 at 6:58 AM
FRIDAY THINGS TO WATCH: 🏦9:45AM: Chicago Fed President Austan Goolsbee gives opening remarks and moderates a panel at the 19th Annual Community Bankers Symposium. 📈10:00AM: Economists watch the preliminary October University of Michigan survey for updates on consumer sentiment and inflation expectations. 📊2:00PM: September Monthly U.S. federal budget will be released 🎮 $EA launches Battlefield 6 on PS5, Xbox Series X|S, and PC with a global simultaneous release. Set in 2027, it depicts a conflict between a fractured NATO and the private military group Pax Armata. 🏀NBA preseason games in Macau’s Venetian Arena feature the Brooklyn Nets vs. Phoenix Suns, boosting The Venetian Macau owned by $SCHYY (a majority subsidiary of $LVS). 🧬 $CRSP, $DTIL, and $MSCLF present at the World Muscle Society Congress.
0 · Reply
fullmetalll
fullmetalll Oct. 8 at 7:03 AM
$MSCLF who the watchers here? We wait
0 · Reply
Florestan
Florestan Oct. 7 at 2:34 PM
$MSCLF highly undervalued for real
0 · Reply
fullmetalll
fullmetalll Oct. 7 at 2:24 PM
$MSCLF Today 4% up
0 · Reply
fullmetalll
fullmetalll Oct. 7 at 2:20 PM
$MSCLF Slow, Volume 34.5K, lets go
1 · Reply
fullmetalll
fullmetalll Oct. 6 at 9:07 PM
$MSCLF The thing here looks like it is completely undervalued. Hardly anyone knows the stock. How should it be known? How should sales come in here? Maybe they can be taken over. Let's go
1 · Reply
fullmetalll
fullmetalll Oct. 6 at 8:15 PM
$MSCLF 116 watchers, what a Joke.
1 · Reply
Latest News on MSCLF
No data available.
Florestan
Florestan Oct. 21 at 3:22 PM
$MSCLF - First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled - 11-month open-label study will evaluate functional outcomes, safety, muscle composition by MRI, and serum biomarkers - Results following initial 3 months of treatment anticipated in early 2026, quarterly thereafter - Planning underway to broaden LT-001 study protocol to enroll new adult patients in Australia and open the study in the U.S., subject to regulatory and clinical site approvals https://ir.satellos.com/news/news-details/2025/Satellos-Announces-First-Adult-Patient-Dosed-in-LT-001-an-Open-Label-Long-Term-Follow-Up-Study-of-SAT-3247-in-Duchenne-Muscular-Dystrophy/default.aspx
0 · Reply
Florestan
Florestan Oct. 21 at 3:21 PM
$MSCLF - First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled - 11-month open-label study will evaluate functional outcomes, safety, muscle composition by MRI, and serum biomarkers - Results following initial 3 months of treatment anticipated in early 2026, quarterly thereafter - Planning underway to broaden LT-001 study protocol to enroll new adult patients in Australia and open the study in the U.S., subject to regulatory and clinical site approvals https://ir.satellos.com/news/news-details/2025/Satellos-Announces-First-Adult-Patient-Dosed-in-LT-001-an-Open-Label-Long-Term-Follow-Up-Study-of-SAT-3247-in-Duchenne-Muscular-Dystrophy/default.aspx
0 · Reply
Florestan
Florestan Oct. 13 at 5:07 PM
$MSCLF https://www.biospace.com/press-releases/satellos-announces-new-data-further-demonstrating-safety-tolerability-and-functional-impact-of-sat-3247-in-first-in-human-trial-of-adults-with-duchenne-muscular-dystrophy
0 · Reply
theoptionsplug
theoptionsplug Oct. 10 at 6:58 AM
FRIDAY THINGS TO WATCH: 🏦9:45AM: Chicago Fed President Austan Goolsbee gives opening remarks and moderates a panel at the 19th Annual Community Bankers Symposium. 📈10:00AM: Economists watch the preliminary October University of Michigan survey for updates on consumer sentiment and inflation expectations. 📊2:00PM: September Monthly U.S. federal budget will be released 🎮 $EA launches Battlefield 6 on PS5, Xbox Series X|S, and PC with a global simultaneous release. Set in 2027, it depicts a conflict between a fractured NATO and the private military group Pax Armata. 🏀NBA preseason games in Macau’s Venetian Arena feature the Brooklyn Nets vs. Phoenix Suns, boosting The Venetian Macau owned by $SCHYY (a majority subsidiary of $LVS). 🧬 $CRSP, $DTIL, and $MSCLF present at the World Muscle Society Congress.
0 · Reply
fullmetalll
fullmetalll Oct. 8 at 7:03 AM
$MSCLF who the watchers here? We wait
0 · Reply
Florestan
Florestan Oct. 7 at 2:34 PM
$MSCLF highly undervalued for real
0 · Reply
fullmetalll
fullmetalll Oct. 7 at 2:24 PM
$MSCLF Today 4% up
0 · Reply
fullmetalll
fullmetalll Oct. 7 at 2:20 PM
$MSCLF Slow, Volume 34.5K, lets go
1 · Reply
fullmetalll
fullmetalll Oct. 6 at 9:07 PM
$MSCLF The thing here looks like it is completely undervalued. Hardly anyone knows the stock. How should it be known? How should sales come in here? Maybe they can be taken over. Let's go
1 · Reply
fullmetalll
fullmetalll Oct. 6 at 8:15 PM
$MSCLF 116 watchers, what a Joke.
1 · Reply
fullmetalll
fullmetalll Oct. 6 at 7:32 PM
$MSCLF What's this? Hardly any watchers, and Phase 2 is in. Surely there should be at least a 300% upside? There are no watchers. Very, very bullish.
1 · Reply
Florestan
Florestan Oct. 6 at 7:14 PM
$MSCLF waiting for our own $SPRB moment... https://ir.satellos.com/news/news-details/2025/Satellos-Announces-IND-Submission-to-the-U-S--FDA-and-Global-Regulatory-Filings-to-Advance-a-Phase-2-Clinical-Trial-of-SAT-3247-in-Children-with-Duchenne-Muscular-Dystrophy/default.aspx
0 · Reply
himdiboss
himdiboss Oct. 3 at 3:28 PM
$MSCLF Okay 👀🚀
0 · Reply
Florestan
Florestan Sep. 29 at 7:04 PM
$MSCLF Game on.
0 · Reply
himdiboss
himdiboss Sep. 29 at 5:30 PM
$MSCLF Wow!! We’re almost to .52 whole cents again 😂😂😂💩
0 · Reply
HamBoneXoXo
HamBoneXoXo Sep. 23 at 5:25 AM
$MSCLF Their pill sounds quite interesting. Totally in a dmd class of its own and worth some investment. They likely got a reverse and raise upon entering nasdaq, so I wonder when is the good time to buy.
1 · Reply
Florestan
Florestan Sep. 22 at 2:21 PM
$MSCLF https://www.businesswire.com/news/home/20250922219476/en/Satellos-Announces-IND-Submission-to-the-U.S.-FDA-and-Global-Regulatory-Filings-to-Advance-a-Phase-2-Clinical-Trial-of-SAT-3247-in-Children-with-Duchenne-Muscular-Dystrophy
0 · Reply
Florestan
Florestan Sep. 18 at 1:53 PM
$MSCLF relatively quiet, for those who did not catch the recent conferences: 1. The P2 clinical package is done and they are in the process of submission. 2. They expect early curve separation between placebo and the doses. 3. They intend to advance FSHD program into the clinic within a year. 4. Their preclinical also include an anti-aging program where they intend to modulate muscle stem cells to divide symmetrically to recreate the muscle growth engine and reverse sarcopenia from old age. <--- this is the blue ocean indication.
0 · Reply
PennyScam
PennyScam Sep. 15 at 2:09 PM
$MSCLF Hi. Steve. You the same Steve as the other Steve? Also, noticed your a eagle and a investor. So was that a paid fluff piece? I ask that only because you missed ICO Therapeutics and its Bertiliumumab ophthalmology indication etc. I think that’s a desirable product to have. I wonder if Astra Zeneca would want that little indication since it’s already taken all other indications for that approved orphan designated drug call Bertiliumumab. It seems to me like they are devouring every little crumb. It’s also strange that these officers have links to good old AZ. Once in the gander, always in the gander. Take it or leave it. One more question. If that wasn’t a paid fluff piece created by you, do you then choose to write articles on companies in your free time? Obviously your invested and you have interest here. I just don’t get if you are a investor why hide the good shit.
0 · Reply
steven5120
steven5120 Sep. 4 at 12:02 AM
$MSCLF $MSCL My article on Satellos was published yesterday on Seeking Alpha. The small phase 1b trial in 5 adult DMD patients treated with an oral pill (5 of 7 days) over 28 days where a doubling (2X) of grip strength was particularly encouraging. Looking forward to results from open label phase 1b 11 mo extension trial. Also looking forward to global phase 2 placebo controlled trial in 51 pediatric DMD patients (under age 12) expedited to be filed in q3 and to begin shortly thereafter. See https://seekingalpha.com/article/4818495-satellos-bioscience-promising-novel-treatment-for-duchenne-muscular-dystrophy
1 · Reply
steven5120
steven5120 Sep. 4 at 12:01 AM
$MSCLF $MSCL My article on Satellos was published yesterday on Seeking Alpha. The small phase 1b trial in 5 adult DMD patients treated with an oral pill (5 of 7 days) over 28 days where a doubling (2X) of grip strength was particularly encouraging. Looking forward to results from open label phase 1b 11 mo extension trial. Also looking forward to global phase 2 placebo controlled trial in 51 pediatric DMD patients (under age 12) expedited to be filed in q3 and to begin shortly thereafter. See https://seekingalpha.com/article/4818495-satellos-bioscience-promising-novel-treatment-for-duchenne-muscular-dystrophy
0 · Reply
Florestan
Florestan Sep. 3 at 7:14 PM
$MSCLF 6.3M shares just changed hands over on Canadian side in a single trade. Likely institutional activities just before FDA go-ahead for P2 dosing.
0 · Reply